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Abstract A 71-year-old woman was admitted to our department because of
acute myocarditis. She was ameliorated with conventional heart failure treatment,
however she developed left ventricular dilatation and cardiac troponin T (cTnT)
was elevated again to >1.0 ng/ml 6 month after the ﬁrst admission. She was re-
admitted because of recurrent decompensated heart failure in spite of conventional
treatment. Right ventricular endomyocardial biopsy revealed active myocarditis.
Immunosuppressive therapy with prednisolone and azathioprine improved her symp-
toms and left ventricular function accompanied by a striking decrease of cTnT levels.
The decreased cTnT level indicated an effective response to immunosuppression
early after the beginning of treatment. These ﬁndings suggested that it is possible
to evaluate the response to immunosuppressive therapy by serial measurement of
cardiac troponin.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
freserved.
Long-term follow-up studies in patients with
acute myocarditis have shown a variable inci-
dence of dilated cardiomyopathy (DCM) [1]. Most
cases of myocarditis are hypothesized to result
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utoimmune phase and then to progressive car-
iac dilatation [2]. There are some patients
ith chronic myocardial inﬂammation who respond
o immunosuppressive therapy (responders) [3,4],
owever the identiﬁcation of these responders
s challenging. Here, we present a case report
f myocarditis with persistently increased car-
gy. Published by Elsevier Ireland Ltd. All rights reserved.
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immunosuppressive therapy for myocarditis with tr
iac troponin T (cTnT) that was treated with
mmunosuppression.
ase Report
71-year-old woman with a history of hyper-
ension and dyslipidemia was admitted to our
epartment on January 5, 2006, 6 months before
he admission discussed in this paper, because
f palpitations and orthopnea. An electrocardio-
ram showed sustained ventricular tachycardia
ith a heart rate of 113/min. A transthoracic
chocardiogram (TTE) showed a non-dilated severe
ypokinetic left ventricle (LV) with thickened sep-
al wall. An emergent coronary angiogram showed
o stenotic lesions. White blood cell (WBC) count,
emoglobin, platelet, and C-reactive protein (CRP)
n admission were 8610/l (band 2%, segment
1%, lymphocyte 10%, monocyte 4%, eosinophil
%), 11.1 g/dl, 193,000/l and 3.65mg/dl, respec-
v
i
n
t
ig. 1 The clinical course is shown for hemodynamics, New
oncentrations of cardiac troponin T (cTnT) and B-type natri
NP parallels the clinical course of recurrent myocarditis and
ndicates an effective response. ACE = angiotensin-converting e
ndex, EMB = endmyocardial biopsy, PCWP=pulmonary capillain 155
ively. Serum creatine kinase levels were elevated
nly up to 160 IU/l, however, cTnT and B-type
atriuretic peptide (BNP) levels were severely ele-
ated to 1.81 ng/ml and 2792 pg/ml, respectively.
BC and CRP were also elevated to 12,710/l
nd 8.59mg/dl, respectively. The clinical course
f cTnT and BNP levels as well as hemodynamics
nd functional class is shown in Fig. 1. During the
rst 2 weeks, electrocardiograms showed various
upraventricular and ventricular tachyarrhythmias.
he patient was required catecholamine support
nly for the ﬁrst week without any mechanical cir-
ulatory support. Her symptoms were ameliorated
nd the arrhythmias disappeared after conven-
ional therapy. The thickness of the septal wall
ecreased and the LV ejection fraction increased,
ut the LV end diastolic dimension enlarged (Fig. 2).
erological studies for coxsackie virus, inﬂuenza
irus, and echovirus were all negative for active
nfection using paired titers. The patient was diag-
osed with acute myocarditis based on elements of
he clinical course.
York Heart Association (NYHA) class, therapy type, and
uretic peptide (BNP). The biphasic increase in cTnT and
the striking decrease after immunosuppressive therapy
nzyme, ARB = angiotensin II receptor blocker, CI = cardiac
ry wedge pressure.
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Fig. 2 M-mode echocardiograms of the left ventricle in the parasternal long-axis view shows gradual enlargement of
ptal
n, LV
The BNP level also decreased, although more
slowly than cTnT. The second endomyocardial
biopsy, which was performed after 14 weeks of
immunosuppressive therapy, revealed a scar-like
Fig. 3 (a) A specimen from an endomyocardial biopsy
performed before immunosuppressive therapy shows
severe lymphocytic inﬁltration compatible with activethe cavity and changes in left ventricular function and se
thickness, LVEDD= left ventricular end diastolic dimensio
Both cTnT and BNP levels were once decreased
to 0.02 ng/ml and <100 pg/ml, respectively, how-
ever, they had been gradually increased for 4
months after the ﬁrst admission (Fig. 1). During the
next month, the patient showed clinical symptoms
such as general fatigue and dyspnea on exertion,
and was re-admitted to our department on July 3,
2006. An electrocardiogram showed sinus rhythm
with paroxysmal atrial contractions with a heart
rate of 91/min. TTE showed severe LV dysfunc-
tion with dilated cavity (Fig. 2), and both cTnT
and BNP levels were severely elevated again to
1.28 ng/ml and 2441 pg/ml, respectively. There was
neither elevation of creatine kinase nor ST-T change
of electrocardiogram. WBC, hemoglobin, platelet,
and CRP on admission this time were 7750/l
(neutrophil 62.3%, lymphocyte 31.6%, monocyte
4.9%, eosinophil 0.8%), 9.5 g/dl, 206,000/l, and
0.23mg/dl, respectively. WBC and CRP were ele-
vated slightly up to 10,560/l and 1.24mg/dl,
respectively, during hospitalization. We performed
thallium scintigraphy that revealed slight hypoup-
take of inferior-lateral apex, however neither
gallium scintigraphy nor positron emission tomog-
raphy was performed. Despite standardized heart
failure treatment, she complained of severe res-
piratory distress at rest and she was hypotensive
with a low output state. A right ventricular endomy-
ocardial biopsy performed 23 days after admission
revealed severe lymphocytic inﬁltration compatible
with active myocarditis (Fig. 3a). Specimens ana-
lyzed by polymerase chain reaction for the presence
of viral genomes were negative for adenovirus,
inﬂuenza virus, and enterovirus.
Immunosuppressive therapy was begun on the
25th hospital day with prednisolone (40mg/day;
1mg/kg for 2 weeks decreased by 5mg per
week until it reached 10mg/day) and azathioprine
(50mg/day; 1.25mg/kg for 14 weeks). Strikingly
the cTnT level decreased to 0.09 ng/ml after 7
days and to 0.01 ng/ml after 12 days (Fig. 1).
m
o
s
l
iwall thicknesses over time. IVST = interventricular septal
EF = left ventricular ejection fraction.yocarditis. (b) A specimen from the second endomy-
cardial biopsy performed 14 weeks after immuno-
uppressive therapy shows scar-like changes and mild
ymphocytic inﬁltration. (Hematoxylin-Eosin, scale-bar
ndicates 20m).
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Rmmunosuppressive therapy for myocarditis with tr
hange and mild lymphocytic inﬁltration (Fig. 3b).
ne year after discharge, cTnT and BNP levels
ere 0.01 ng/ml and <200 pg/ml, respectively. TTE
howed mild impaired LV function with dilated LV
avity (Fig. 2) while the patient received continuous
dministration of prednisolone at 10mg/day. The
atient has remained symptom-free for more than
year.
iscussion
he natural history of symptomatic myocarditis
aries from early death by fulminant myocardi-
is or ventricular arrhythmia to complete recovery
r long-term evolution to DCM [1]. Evidence is
ccumulating that myocarditis and DCM are closely
elated, though we have not yet found the miss-
ng link. The current concept of the disease process
tarts with an initial myocardial injury, and ends in
healed state in most cases, although it can also
e followed by a second phase involving autoim-
une processes which then progresses to the ﬁnal
tage of DCM [5]. In this case, we found persistent
ncreases in cTnT levels and progressive LV remod-
ling after the remission of initial myocardial injury,
hich suggests the presence of chronic myocardial
amage in the second phase.
Patients with well-established DCM do not
espond to immunosuppressive therapy [6], prob-
bly because they have reached the ﬁnal stage
n which there are no remaining active inﬂamma-
ory lesions. The only published randomized and
ouble-blinded trial of immunosuppressive therapy
Myocarditis Treatment Trial; MTT) showed neither
eneﬁt nor harm of immunosuppression [7]. Sub-
roup analysis of the MTT study found only one-third
f patients have elevated cardiac troponin I lev-
ls, and these increases were correlated with heart
ailure symptoms lasting ≤1 month [8], suggest-
ng that a minority of people in the MTT study
ere experiencing chronic myocardial damage in
he second phase. On the other hand, immuno-
uppressive therapy is beneﬁcial for patients with
uman leukocyte antigen up-regulation [3] or those
ith circulating cardiac autoantibodies and no viral
enome in the myocardium [4]. These two trials
nd the present case involved patients experi-
ncing heart failure symptoms for more than 6
onths, suggesting that responders must be inhe chronic phase. We used azathioprin in addi-
ion to steroid because all patients who were
esponded to immunosuppressive therapy were
reated with azathioprin in MTT and these two
rials.in 157
Cardiac troponins are sensitive and speciﬁc
arkers of myocardial injury. The magnitude of
roponin elevation in patients with heart failure
as been correlated with the severity of the dis-
ase and with adverse outcomes [9]. Elevated
roponin levels in patients with heart failure may
uggest ongoing myocardial damage and may serve
s a marker for the progression of heart failure
10]. In this case, we were able to assess the
esponse only a week after beginning immunosup-
ressive therapy by measuring the rapid decrease
f cTnT levels. If decreased cTnT is a common
haracteristic in responders, a patient’s response
ould be determined by performing a short-term
mmunosuppressive therapeutic diagnostic trial.
dditionally, decreases of cTnT would indicate that
utoimmune reactions are involved in myocardial
amage.
This is a case report where levels of cTnT were
easured to evaluate the response to immunosup-
ressive therapy for myocarditis. Base on this single
ase, it might be able to distinguish responder and
on-responder with short-term immunosuppressive
rial to measure serial cTnT levels, however, we
eed more cases to prove whether it is true or not.
n conclusion, serial cTnT measurements may be
noninvasive and accurate method to conﬁrm the
esponse to immunosuppressive therapy.
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